首页> 外文会议>Conference on Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy Ⅺ Jan 19-20, 2002 San Jose, USA >CLINICAL STUDIES OF PHOTODYNAMIC THERAPY FOR MALIGNANT BRAIN TUMORS: Karnofsky score and neurological score in patients with recurrent gloms treated with Photofrin-PDT
【24h】

CLINICAL STUDIES OF PHOTODYNAMIC THERAPY FOR MALIGNANT BRAIN TUMORS: Karnofsky score and neurological score in patients with recurrent gloms treated with Photofrin-PDT

机译:光敏疗法治疗恶性脑肿瘤的临床研究:Photofrin-PDT治疗复发性胶质瘤患者的卡氏评分和神经系统评分

获取原文
获取原文并翻译 | 示例

摘要

In our previous phase II studies we treated 112 patients with malignant brain tumors with 2-mg/kg Photofrin i.v. and intra-operative cavitary PDT. We concluded that PDT was safe in patients with newly diagnosed or recurrent supratentorial malignant gliomas. Pathology, performance grade and light dose were significantly related to survival time. In selected patients when an adequate light dose was used survival time improved. The surgical mortality rate was less than 3%. [spie 2000] We have initiated two randomized prospective trials - the first, to determine if the addition of PDT to standard therapy [surgery, radiation and/or chemotherapy] prolongs the survival of patients with newly diagnosed malignant astrocytic tumors; and the second, to determine whether high light dose PDT [120 J/cm~2] is superior to low light dose PDT [40 J/cm~2] in patients with recurrent malignant astrocytic tumors. To date, 158 patients have been recruited ― 72 to the newly diagnosed malignant glioma study and 86 to the recurrent glioma study. In the recurrent glioma study we compared the pre-operative KS and elements of the neurological examination [speech function, visual fields, cognitive function, sensory examination and gait] to the post-operative examinations at hospital discharge. The means were compared by paired student-t test. The KS in 86 of 88 patients with recurrent gliomas were assessable. The mean [s.d.] preoperative and post-operative KS were 82 +- 14 and 79 +- 17, respectively [p=0.003]. The mean decline in KS, although statistically significant, was small and of no clinical importance. The median Karnofsky score changed from 90 to 80. The KS improved in 8 patients; their post-operative average length of stay (alos) was =9.7 days. There was no change in 47 [alos=8.3], a decline of 10 points in 24 [aloc=13.4] and declined by more than 10 points in 7 [alos=23.3]. Three of these 7 patients who had a decline of >10 points improved in follow-up but did not reach their preoperative KS. The data were not available in 2. A small but statistically significant decline in Karnofsky score was identified post-operatively in these recurrent tumor patients. Their hospital average length of stay increased with declining Karnofsky score. These prospective clinical observations confirmed our previous conclusion that brain tumor PDT was safe. The clinical studies are supported in part by grant CA 43892 awarded by DHHS/NIH/NCl.
机译:在之前的II期研究中,我们用2 mg / kg Photofrin i.v.治疗112例恶性脑肿瘤患者。术中腔内PDT。我们的结论是,PDT在新诊断或复发的幕上恶性神经胶质瘤患者中是安全的。病理,性能等级和光剂量与生存时间显着相关。在选定的患者中,当使用足够的轻剂量时,生存时间得到改善。手术死亡率低于3%。 [spie 2000]我们已经启动了两项随机的前瞻性试验-第一项是确定在标准疗法[手术,放疗和/或化疗]中添加PDT是否能延长新诊断为恶性星形细胞肿瘤的患者的生存期;第二,确定复发性恶性星形细胞肿瘤患者中高剂量PDT [120 J / cm〜2]是否优于低剂量PDT [40 J / cm〜2]。迄今为止,已经招募了158位患者,其中72位接受了新诊断的恶性神经胶质瘤研究,86位接受了复发性胶质瘤研究。在复发性神经胶质瘤研究中,我们比较了术前KS和神经系统检查的要素(语音功能,视野,认知功能,感觉检查和步态)与出院后的术后检查。均数通过配对学生t检验进行比较。 88例胶质瘤复发患者中有86例的KS可评估。术前和术后KS的平均[s.d.]分别为82±14和79±17 [p = 0.003]。 KS的平均下降虽然有统计学意义,但很小,没有临床意义。 Karnofsky评分的中位数从90变为80。8例患者的KS改善了。他们的术后平均住院时间为9.7天。 47例[alos = 8.3]没有变化,24例[aloc = 13.4]下降了10点,7例[alos = 23.3]下降了10点以上。下降> 10分的这7例患者中有3例随访改善,但未达到术前KS。在2中没有可用的数据。在这些复发性肿瘤患者的手术后,发现Karnofsky评分略有下降,但有统计学意义。他们的平均住院时间随着Karnofsky分数的下降而增加。这些前瞻性临床观察证实了我们先前的结论,即脑肿瘤PDT是安全的。临床研究部分由DHHS / NIH / NCl授予的CA 43892资助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号